

Sort Out Alternative Status Epilepticus Medications

Medication shortages and new drug formulations will bring up questions about how to treat status epilepticus.

Continue using benzos first-line for emergent treatment. Lorazepam 0.1 mg/kg IV to a max of 4 mg per dose is preferred...but we know it's commonly on shortage.

Keep other benzo options and routes in mind...in case you can't get lorazepam. Try midazolam injection IM or intranasally...or buccally in a pinch. Or you can give diazepam injection IV, intranasally, or rectally.

Use caution giving IV midazolam boluses. There isn't good evidence for dosing or conversions from IV lorazepam...although some experts use a 2 mg midazolam to 1 mg lorazepam conversion.

Add or update these benzo options in your EHR...and think about creating order sets...for easier prescribing. And stock them in key patient units...such as the ED and ICUs...depending on hospital policy.

Clarify urgent second-line options.

Move to a second-line med for seizures lasting a total of 20 minutes or more despite benzos.

Fosphenytoin, levetiracetam, and valproic acid are equally effective at stopping status epilepticus...for patients 2 years and up.

Standardize your hospital's practices and choose an agent you can use promptly. The longer seizures continue, the more likely the patient will be unresponsive to meds...causing neurological damage.

Consider using levetiracetam first to save time...commercially made vials can be stored on the unit to give IV push. Fosphenytoin and valproic acid need to be diluted first and require longer infusion times.

Plus levetiracetam has fewer interactions or adverse effects. Recommend it as a safer option if a medication history isn't available.

Be aware, new evidence suggests higher levetiracetam IV push doses are safe...up to 4,500 mg in adults and 60 mg/kg in kids. Remember that doses using more than 3 vials (1,500 mg) at the bedside require multiple syringes...due to new USP 797 rules for sterile immediate-use meds.

Phenobarbital and lacosamide are also second-line options...and can be given undiluted if needed. But they have adverse effects (hypotension, respiratory depression, etc) if infused too quickly.

Use the new preservative-free phenobarbital injection (*Sezaby*) for newborn seizures only. It's not approved for older kids and adults.

Move to third-line options for refractory seizures.

Give another second-line med...or recommend a propofol or midazolam titratable infusion. Expect patients with these continuous infusions to need intubation...and continuous EEG monitoring.

Don't be surprised if these patients need higher infusion rates than you usually see for sedation. Tailor your infusion pump guardrails to safely allow these higher rates when needed.

See our chart, *Pharmacotherapy of Status Epilepticus*, for more dosing details...and other options for refractory cases including ketamine and pentobarbital.

Key References:

Cite this document as follows: Article, Sort Out Alternative Status Epilepticus Medications, Hospital Pharmacist's Letter, October 2024

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email sales@trchealthcare.com.

© 2024 Therapeutic Research Center (TRC). TRC and Hospital Pharmacist's Letter and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved.

- Chamberlain JM, Kapur J, Shinnar S, et al; Neurological Emergencies Treatment Trials; Pediatric Emergency Care Applied Research Network investigators. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. *Lancet*. 2020 Apr 11;395(10231):1217-1224.
- Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. *Epilepsy Curr*. 2016 Jan-Feb;16(1):48-61.
- Price L, Garrity L, Stiehl S. Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution. *Pharmacotherapy*. 2024 Feb;44(2):141-148.
- Koons M, Koehl J, Johnson R, et al. Efficiency and safety of high-dose undiluted intravenous push levetiracetam loading doses compared to intravenous infusion in seizing patients: A retrospective cohort study. *Epilepsia*. 2024 Aug 10. doi: 10.1111/epi.18079.

Hospital Pharmacist's Letter. October 2024, No. 401013

Cite this document as follows: Article, Sort Out Alternative Status Epilepticus Medications, Hospital Pharmacist's Letter, October 2024

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email sales@trchealthcare.com.

© 2024 Therapeutic Research Center (TRC). TRC and Hospital Pharmacist's Letter and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved.